Maia Anderson –
Thursday, October 29th, 2020
More articles on pharmacy: Regeneron states its COVID-19 antibody cocktail reveals promise in moderate to moderate casesGileads income increases by 17%, driven by remdesivir salesSunstar recalls gingivitis drug due to possible bacterial contamination.
Read the complete short article here.
The drugmaker needs to show the vaccine is at least 74 percent efficient in the first review, and 57 percent reliable in the 2nd evaluation. The FDA requires at least 50 percent efficacy in the last analysis, however Moderna has stated it desires at least 75 percent efficacy overall, The Hill reported..
Moderna CMO Tal Zaks, MD, PhD, stated Oct. 29 the drugmaker is on track to report initial outcomes from its COVID-19 vaccine trial in November, The Hill reported..
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
On an incomes call, Dr. Zaks said Modernas trial is running as prepared and an independent information keeping track of committee anticipates to perform an interim evaluation in November. The very first evaluation will occur after the trial reports 53 participants have actually evaluated favorable for COVID-19 and a 2nd is to occur after 106 participants test positive, The Hill reported.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.
Moderna has gotten $1.1 billion in deposits from a number of federal governments to provide them with the vaccine, according to The Hill. CEO Stéphane Bancel has said the business expects to produce 20 million dosages by the end of the year and between 500 million and 1 billion dosages next year..